Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia

Current strategies for the treatment of acute myeloid leukemia (AML) focus on the induction of cell death by standard chemotherapy or targeted therapy. In elderly patients with chemorefractory disease the prognosis is still poor and allogeneic hematopoietic stem cell transplantation is rarely